Less than a year after success in animals, the first drug in the world that can regenerate teeth will begin human trials in a few months, according to News Atlas.
This opens the door for the drug to be commercially available as early as 2030, the report said.
From September 2024 to August 2025, Kyoto University Hospital in Japan will treat 30 men between the ages of 30 and 64 who have at least one mole removed.
The vein therapy will be tested for effectiveness in human bites after the results of new tooth growth without significant impact in dental and mouse models.
“We want to do something to help people who have lost teeth or are missing teeth,” said Katsu Takahashi, chief of dentistry and oral surgery at Kitano Hospital.
“Although there is currently no treatment that provides a permanent cure, we feel that the public’s expectations for tooth growth are high.”
After the first 11-month phase, researchers will conduct experiments on patients between the ages of two and seven who have lost at least four teeth due to tooth loss, which affects about one percent of people.
The lawsuit would also apply to people who have partial edentulism or who have lost one to five permanent teeth due to environmental factors.
This drug blocks the gene-1 (USAG-1) protein associated with uterine sensitivity by inhibiting tooth development.
According to News Atlas, it stimulates bone morphogenetic protein (BMP) signaling by blocking the interaction of USAG-1 with other proteins.
